Nearly 1 in 3 deaths in the USA are caused by heart disease and stroke. Of the approximately 1.5 million people suffering heart attacks annually in the U.S., more than 250,000 will die within one hour of their incident. Unfortunately, for up to 50% of these individuals, the FIRST SYMPTOM of coronary artery disease is sudden cardiac death, or a heart attack.
Lexington Biosciences, Inc. (OTC: LXGTF) aims to provide the solution to early detection by introducing HEARTSENTRY, a revolutionary, simple and effective technology for personalized measurement and monitoring of vascular health to detect the potential for cardiovascular disease at its earliest stages. HEARTSENTRY is designed to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of heart attacks and stroke.
This is Simple… Lexington Biosciences, Inc. (OTC: LXGTF) is providing a simple, non-invasive, effective & low cost early detection medical device that has the potential to SAVE LIVES!
HEARTSENTRY is effective. How effective? According to Lexington Biosciences, Inc. (OTC: LXGTF) Investor Presentation (found here) it’s sensitivity is 500% improved over ultrasound, provides a consistently higher accuracy with lower variability than ultrasound and finally is faster & easier to use!
Fast Tracked for FDA Approval
When lives are on the line there is no time to waste! Lexington Biosciences, Inc. (OTC: LXGTF) is wasting no time getting HEARTSENTRY approved by the FDA. In-fact HEARTSENTRY was SUBMITTED & APPROVED for the FDA’s Expedited Access Pathway (EAP) program.
This a voluntary program for certain medical devices like HEARTSENTRY that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), premarket notification (510[k]) or requests for De Novo designation.
Under EAP, the FDA works with device sponsors to try to reduce the time and cost from development to marketing decision without changing the FDA’s PMA approval standard of reasonable assurance of safety and effectiveness, the standards for granting De Novo requests, or any other standards of valid scientific evidence.
It’s worth noting that to gain the approval HEARTSENTRY did for the FDA’s (EAP) program they had to meet the following criteria:
- Provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.
AND ONE OF THE FOLLOWING:
- Represent breakthrough technologies.
- No approved or cleared alternatives exist
- Offer clinically meaningful advantages over existing approved or cleared alternatives including the potential, when compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’ ability to manage their own care (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or the availability of which is in the best interest of patients.
When Was the Last Time You Had the Opportunity to Invest in a Company Pre-FDA Approval with an ACTUAL CHANCE of Being Approved?
Let’s Talk Opportunity!
How Does $140,000,000,000 Sound?
Lexington Biosciences, Inc. (OTC: LXGTF) is in the $140-billion-dollar medical device & diagnostic sector. The company has a real product that has a real chance of being FDA approved… what do you think happens if that comes to be?
To help paint this picture allow us to use an example of a similar product to HEARTSENTRY, the FDA approved iHealth Wireless Blood Pressure Monitor. This device currently retails at:
We don’t know for sure but would assume that if you are being sold in 4 of the biggest big box retailers on the planet that your business is doing well… again just a “guess” on our part. What do you think?
It would stand to reason that Lexington Biosciences, Inc. (OTC: LXGTF)’s product HEARTSENTRY if approved by the FDA could have the same retail distribution.
If FDA approval & big box retail distribution happens for HEARTSENTRY our guess is that the company will thrive not to mention the potential extreme positive reaction in the public markets for the company’s stock (OTC: LXGTF).
To further demonstrate our point of potential let’s discuss iRhythm Technologies (NASDAQ:IRTC). Founded in 2005 by physicians & engineers, iRhythm Technologies remotely measure and diagnoses cardiac arrhythmias. This company uses cloud connected wearable bio-sensing technology as both device and service. iRhythm Technologies (NASDAQ:IRTC)’s IPO took place in mid-October 2016 & began trading at around $25.00usd per share.
Less Than 2 Years Later (NASDAQ:IRTC) is Trading Over $63.00usd Per Share. That is a Gain of 152%!
You should be asking yourself the following… Just because other public companies within this sector have those kind of results does that mean Lexington Biosciences, Inc. (OTC: LXGTF) will? Unfortunately, no-one has a “crystal ball” but since we aren’t trying to guess the winning lottery #’s we can make proper educated comparisons based on companies who have had success in both business and on the public markets.
Look at the stock charts below 1st you will see a chart (OTC: LXGTF) and then below, you will see (NASDAQ:IRTC).
Whereas (NASDAQ:IRTC) has been actively trading for almost 2 years on the NASDAQ, (OTC: LXGTF) just became consistently active within the OTC Markets at the end of September 2017.
Anything Look Similar?
Have You Spotted a Ground Floor Opportunity?
Behind Every Successful Company is an Elite Management Team
The principals, directors and advisers of Lexington Biosciences, Inc. (OTC: LXGTF) have been individually and collectively involved in raising extensive capital funding for their private and public companies. Team members have held numerous executive leadership positions encompassing biotechnology, and medical device companies, as well as multi-national corporations. The team includes inventors, scientists, and business people who have successfully started, built and grown multiple life science companies.
Eric Willis, Chief Executive Officer
Mr. Willis is an entrepreneurial healthcare technology executive with a track record of success in bringing products from initial concept to market. He is the past President and Chief Operating Officer of ParaPatch (2013–2015), where he was responsible for the development and launch of an over-the-counter women’s health product for the treatment of urinary incontinence. Prior to this, he served as President and CEO of InSite Medical Technologies (2008–2013) a venture backed start-up medical device company that developed a new method for performing epidural anesthesia. From 1994–2008 he served in a variety of executive and operational roles for cardiovascular medical device companies.
Rocco Rossi, Director
A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. His unique blend of experience intersects general management, philanthropy, public policy, politics, business strategy, and new media. As CEO of the Heart and Stroke Foundation – one of Canada’s largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over $500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP.
Doug Janzen, Chairman
Mr. Janzen has 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Mr. Janzen is currently Co-Founder and Managing Director of Northview Ventures. He serves as Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, he was President and CEO of Cardiome Pharma (NASDAQ: CRME) During this time he raised over $300 million from investors, completed over $1 billion in licensing deals.
Greg Robertson, M.D., Medical Advisor
Dr. Greg Robertson is chief of the Emory Heart and Vascular Clinic at Johns Creek. At the Emory Johns Creek Hospital he is chief of cardiology and the medical director of the cardiac catheterization laboratory and interventional program. He is board certified in Vascular Medicine, Endovascular Medicine, Interventional Cardiology and Cardiovascular Medicine. He is an associate professor of medicine at Emory University. Dr. Robertson’s clinical expertise has focused on preventative care and using minimally-invasive vascular and cardiac treatment.
Listen Carefully… Opportunity is Knocking
It’s not everyday you are presented with the opportunity of investing in a company that’s within a $140-billion-dollar sector, with a real chance for FDA approval, the potential opportunity to sell their product within some of the largest big box retailers on the planet, the chance to capitalize off of a hot sector with public companies currently making triple digit gains in less than 2 years & not to mention you get to be a part of the beginnings of a company that’s primary goal is to SAVE LIVES!
Midam Ventures, LLC has been compensated $100,000.00 by Ellis Stewart, LLC for a period beginning October 1, 2017 and ending November. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning November 1, 2017 and ending December. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning December 1, 2017 and ending December 31, 2017 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Midam Ventures, LLC has been compensated an additional $250,000.00 by Ellis Stewart, LLC for a period beginning January 1, 2018 and ending February 1, 2018 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.